Early Effects of Low Molecular Weight Heparin Therapy with Soft-Mist Inhaler for COVID-19-Induced Hypoxemia: A Phase IIb Trial

Basit Öğe Kaydı
dc.authoridSAHIN, Gokben/0000-0003-2232-3030
dc.authoridYildizPekoz, Ayca/0000-0003-2243-6684
dc.authoridAkbal-Dagistan, Ozlem/0000-0002-6524-3535
dc.authoridKaşkal, Mert/0000-0002-2220-8529
dc.authoridDagistanli, Ahmet Serhan/0000-0002-7953-3824
dc.authoridBasarir, Nur/0000-0002-0695-5292
dc.authoridErturk, Aybige/0000-0002-5179-5865
dc.authorwosidSAHIN, Gokben/HZL-3046-2023
dc.authorwosidYildizPekoz, Ayca/AAD-7826-2020
dc.authorwosidIssever, Halim/AAV-1006-2020
dc.authorwosidAkbal-Dagistan, Ozlem/Q-1443-2019
dc.authorwosidKaşkal, Mert/HKW-1331-2023
dc.contributor.authorErelel, Mustafa
dc.contributor.authorKaskal, Mert
dc.contributor.authorAkbal-Dagistan, Ozlem
dc.contributor.authorIssever, Halim
dc.contributor.authorDagistanli, Ahmet Serhan
dc.contributor.authorBalkanci, Hilal
dc.contributor.authorOguz, Merve Sinem
dc.date.accessioned2024-06-12T10:58:45Z
dc.date.available2024-06-12T10:58:45Z
dc.date.issued2021
dc.departmentTrakya Üniversitesien_US
dc.description.abstractIn COVID-19-induced acute respiratory distress syndrome, the lungs are incapable of filling with sufficient air, leading to hypoxemia that results in high mortality among hospitalized patients. In clinical trials, low-molecular-weight heparin was administered via a specially designed soft-mist inhaler device in an investigator initiated, single-center, open-label, phase-IIb clinical trial. Patients with evidently worse clinical presentations were classed as the Device Group ; 40 patients were given low-molecular-weight heparin via a soft mist inhaler at a dose of 4000 IU per administration, twice a day. The Control Group, also made up of 40 patients, received the standard therapy. The predetermined severity of hypoxemia and the peripheral oxygen saturation of patients were measured on the 1st and 10th days of treatment. The improvement was particularly striking in cases of severe hypoxemia. In the 10-day treatment, low-molecular-weight heparin was shown to significantly improve breathing capability when delivered via a soft-mist inhaler.en_US
dc.identifier.doi10.3390/pharmaceutics13111768
dc.identifier.issn1999-4923
dc.identifier.issue11en_US
dc.identifier.pmid34834183en_US
dc.identifier.scopus2-s2.0-85117928600en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.urihttps://doi.org/10.3390/pharmaceutics13111768
dc.identifier.urihttps://hdl.handle.net/20.500.14551/20183
dc.identifier.volume13en_US
dc.identifier.wosWOS:000727143300001en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherMdpien_US
dc.relation.ispartofPharmaceuticsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectCOVID-19en_US
dc.subjectLow-Molecular-Weight Heparinen_US
dc.subjectSoft-Mist Inhaleren_US
dc.subjectPulmonaryen_US
dc.subjectAnti-Coagulanten_US
dc.subjectBerlin Definitionen_US
dc.subjectMortalityen_US
dc.subjectReceptoren_US
dc.subjectBindingen_US
dc.subjectVirusen_US
dc.subjectArdsen_US
dc.titleEarly Effects of Low Molecular Weight Heparin Therapy with Soft-Mist Inhaler for COVID-19-Induced Hypoxemia: A Phase IIb Trialen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu